Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Experimentelle Pathologie|January 1, 1978
N,N-diethyl-4-aminoazobenzene (DEAB): acute actions with respect to possible carcinogenicity as well as the role of solvents. Morphological and pharmacological investigationsM Danz, W Klinger, D Müller, et al.
Toxicology|October 1, 1988
Chlorinated drinking water is mutagenic and causes 3-methylcholanthrene type induction of hepatic monooxygenaseA Liimatainen, D Müller, T Vartiainen, et al.
Breast Cancer Research and Treatment|June 27, 2003
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapyI Vergote, J F R Robertson, U Kleeberg, et al.
The Science of the Total Environment|December 24, 2019
Zinc isotopic variation of water and surface sediments from the German Elbe RiverT Zimmermann, A F Mohamed, A Reese, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1992
Sequential methotrexate and 5-fluorouracil (FU) vs. FU alone in metastatic colorectal cancer. Results of a randomized multicenter trial. The Association of Medical Oncology (AIO) of the German Cancer SocietyR Herrmann, A Knuth, U Kleeberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1989
Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial GroupM Kaufmann, W Jonat, U Kleeberg, et al.
British Journal of Cancer|May 11, 2006
The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trialS-E Al-Batran, J Bischoff, G von Minckwitz, et al.
Anti-Cancer Drugs|August 13, 2005
Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBCG von Minckwitz, I Chernozemsky, L Sirakova, et al.
Pageof 3